|
| In vivo selection of tumorspecific antibodies |
|
https://doi.org/10.18632/oncotarget.1407
David Sánchez-MartÃn, Laura Sanz, Erkki Ruoslahti, and Luis Alvarez-Vallina
|
| 1547 |
|
| Estrogen response in luminal breast cancer |
|
https://doi.org/10.18632/oncotarget.1354
Leticia B A Rangel, and Tim Hui-Ming Huang
|
| 1548-1549 |
|
| IκBα beyond the NFkB dogma |
|
https://doi.org/10.18632/oncotarget.1325
MarÃa Carmen Mulero, Anna Bigas, and LluÃs Espinosa
|
| 1550-1551 |
|
| Cytokineinduced ‘bystander’ senescence in DDR and immunosurveillance |
|
https://doi.org/10.18632/oncotarget.1487
Zdenek Hodny, Sona Hubackova, and Jiri Bartek
|
| 1552-1553 |
|
| Ribosomes: the future of targeted therapies |
|
https://doi.org/10.18632/oncotarget.1511
Virginie Marcel, Frédéric Catez, and Jean-Jacques Diaz
|
| 1554-1555 |
|
| Lysinespecific modifications of p53: a matter of life and death |
|
https://doi.org/10.18632/oncotarget.1436
Diana Marouco, Alexander V Garabadgiu, Gerry Melino, and Nick A Barlev
|
| 1556-1571 |
|
| The predictive value of 53BP1 and BRCA1 mRNA expression in advanced nonsmallcell lung cancer patients treated with firstline platinumbased chemotherapy |
|
https://doi.org/10.18632/oncotarget.1157
Laura Bonanno, Carlota Costa, Margarita Majem, Jose Javier Sanchez, Ana Gimenez-Capitan, Ignacio Rodriguez, Alain Vergenegre, Bartomeu Massuti, Adolfo Favaretto, Massimo Rugge, Cinta Pallares, Miquel Taron, and Rafael Rosell
|
| 1572-1581 |
|
| High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients |
|
https://doi.org/10.18632/oncotarget.1050
Marc Delord, Philippe Rousselot, Jean-Michel Cayuela, François Sigaux, Joëlle Guilhot, Claude Preudhomme, François Guilhot, Pascale Loiseau, Emmanuel Raffoux, Daniela Geromin, Emmanuelle Genin, Fabien Calvo, and Heriberto Bruzzoni-Giovanelli
|
| 1582-1591 |
|
| Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer |
|
https://doi.org/10.18632/oncotarget.1148
Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A O’Brien, Ioannis Roxanis, Ji-Liang Li, Esther Bridge, Richard Finn, Dennis Slamon, Patricia McGowan, Michael J. Duffy, Norma O’Donovan, John Crown, and Anthony Kong
|
| 1592-1605 |
|
| Smallmolecule targeting of translation initiation for cancer therapy |
|
https://doi.org/10.18632/oncotarget.1186
Bertal H. Aktas, Yuan Qiao, Esra Ozdelen, Roland Schubert, Sema Sevinc, Fred Harbinski, Luciano Grubissich, Samuel Singer, and Jose A. Halperin
|
| 1606-1617 |
|
| Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 downregulation in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.1221
Catia Giovannini, Michele Baglioni, Marco Baron Toaldo, Cristiano Ventrucci, Stefania D'Adamo, Mario Cipone, Pasquale Chieco, Laura Gramantieri, and Luigi Bolondi
|
| 1618-1631 |
|
| The FAK scaffold inhibitor C4 disrupts FAKVEGFR3 signaling and inhibits pancreatic cancer growth |
|
https://doi.org/10.18632/oncotarget.1365
Elena Kurenova, Jianqun Liao, Di-Hua He, Darrell Hunt, Michael Yemma, Wiam Bshara, Mukund Seshadri, and William G Cance
|
| 1632-1646 |
|
| The discovery of potent ribosomal S6 kinase inhibitors by highthroughput screening and structureguided drug design |
|
https://doi.org/10.18632/oncotarget.1255
Sylvain Couty, Isaac M. Westwood, Andrew Kalusa, Celine Cano, Jon Travers, Kathy Boxall, Chiau Ling Chow, Sam Burns, Jessica Schmitt, Lisa Pickard, Caterina Barillari, P. Craig McAndrew, Paul A. Clarke, Spiros Linardopoulos, Roger J. Griffin, G. Wynne Aherne, Florence I. Raynaud, Paul Workman, Keith Jones, and Rob L.M. van Montfort
|
| 1647-1661 |
|
| HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma |
|
https://doi.org/10.18632/oncotarget.1232
Bryce P Portier, Eugen C. Minca, Zhen Wang, Christopher Lanigan, Aaron M. Gruver, Erinn Downs-Kelly, G. Thomas Budd, and Raymond R. Tubbs
|
| 1662-1672 |
|
| Regulation of histone H2AZ expression is mediated by sirtuin 1 in prostate cancer |
|
https://doi.org/10.18632/oncotarget.1237
Tiago Baptista, Inês Graça, Elsa J Sousa, Ana I Oliveira, Natália R Costa, Pedro Costa-Pinheiro, Francisco Amado, Rui Henrique, and Carmen Jeronimo
|
| 1673-1685 |
|
| Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration |
|
https://doi.org/10.18632/oncotarget.1265
Sandra Cascio, Adam M Farkas, Rebecca P Hughey, and Olivera J Finn
|
| 1686-1697 |
|
| Lung cancer tumorigenicity and drug resistance are maintained through ALDHhi CD44hi tumor initiating cells |
|
https://doi.org/10.18632/oncotarget.1246
Jing Liu, Zhijie Xiao, Sunny Kit-Man Wong, Vicky Pui-Chi Tin, Ka-Yan Ho, Junwen Wang, Mai-Har Sham, and Maria Pik Wong
|
| 1698-1711 |
|
| DHHRHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3GLIS2positive acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.1280
Riccardo Masetti, Marco Togni, Annalisa Astolfi, Martina Pigazzi, Elena Manara, Valentina Indio, Carmelo Rizzari, Sergio Rutella, Giuseppe Basso, Andrea Pession, and Franco Locatelli
|
| 1712-1720 |
|
| Substantial expression of luteinizing hormonereleasing hormone LHRH receptor type I in human uveal melanoma |
|
https://doi.org/10.18632/oncotarget.1379
Andrea Treszl, Zita Steiber, Andrew V Schally, Norman L Block, Balazs Dezso, Gabor Olah, Bernadett Rozsa, Klara Fodor, Armin Buglyo, Janos Gardi, Andras Berta, and Gabor Halmos
|
| 1721-1728 |
|
| Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine |
|
https://doi.org/10.18632/oncotarget.1412
Sevin Turcan, Armida WM Fabius, Alexandra Borodovsky, Alicia Pedraza, Cameron Brennan, Jason Huse, Agnes Viale, Gregory J Riggins, and Timothy A Chan
|
| 1729-1736 |
|
| 5azacytidine reduces methylation promotes differentiation and induces tumor regression in a patientderived IDH1 mutant glioma xenograft |
|
https://doi.org/10.18632/oncotarget.1408
Alexandra Borodovsky, Vafi Salmasi, Sevin Turcan, Armida W. M. Fabius, Gilson Baia, Charles G Eberhart, Jon D. Weingart, Gary L Gallia, Stephen B Baylin, Timothy A Chan, and Gregory J Riggins
|
| 1737-1747 |
|
| CCAT2 a novel long noncoding RNA in breast cancer: expression study and clinical correlations |
|
https://doi.org/10.18632/oncotarget.1292
Roxana S Redis, Anieta M Siewerts, Maxime P Look, Oana Tudoran, Cristina Ivan, Riccardo Spizzo, Xinna Zhang, Vanja de Weerd, Masayoshi Shimizu, Hui Ling, Rares Buiga, Victor Pop, Alexandru Irimie, Riccardo Fodde, Isabella Bedrosian, John WM Martens, John A Foekens, Ioana Berindan-Neagoe, and George A Calin
|
| 1748-1762 |
|
| Identification of novel small molecule inhibitors of centrosome clustering in cancer cells |
|
https://doi.org/10.18632/oncotarget.1198
Eiko Kawamura, Andrew B. Fielding, Nagarajan Kannan, Aruna Balgi, Connie J. Eaves, Michel Roberge, and Shoukat Dedhar
|
| 1763-1776 |
|
| Immunological targeting of tumor cells undergoing an epithelialmesenchymal transition via a recombinant brachyuryyeast vaccine |
|
https://doi.org/10.18632/oncotarget.1295
Duane H. Hamilton, Mary T. Litzinger, Alessandra Jales, Bruce Huang, Romaine I. Fernando, James W. Hodge, Andressa Ardiani, David Apelian, Jeffrey Schlom, and Claudia Palena
|
| 1777-1790 |
|
| Upregulation of adenylate cyclase 3 ADCY3 increases the tumorigenic potential of cells by activating the CREB pathway |
|
https://doi.org/10.18632/oncotarget.1324
Seung-Hyun Hong, Sung-Ho Goh, Sang-Jin Lee, Jung-Ah Hwang, Jieun Lee, Il-Ju Choi, Hyehyun Seo, Jong-Hoon Park, Hiromu Suzuki, Eiichiro Yamamoto, In-Hoo Kim, Jin Sook Jeong, Mi Ha Ju, Dong-Hee Lee, and Yeon-Su Lee
|
| 1791-1803 |
|
| Cholesterolinduced mammary tumorigenesis is enhanced by adiponectin deficiency: role of LDL receptor upregulation |
|
https://doi.org/10.18632/oncotarget.1364
Jing Liu, Aimin Xu, Karen Siu-Ling Lam, Nai-Sum Wong, Jie Chen, Peter R R Shepherd, and Yu Wang
|
| 1804-1818 |
|
| Identification of a novel peptide that blocks basic fibroblast growth factormediated cell proliferation |
|
https://doi.org/10.18632/oncotarget.1312
Xiaoping Wu, Huixian Huang, Cong Wang, Shaoqiang Lin, Yadong Huang, Yi Wang, Guang Liang, Qiuxia Yan, Jian Xiao, Jianzhang Wu, Yongguang Yang, and Xiaokun Li
|
| 1819-1828 |
|
| Broadspectrum antitumor and antimetastatic DNA vaccine based on p62encoding vector |
|
https://doi.org/10.18632/oncotarget.1397
Franco Venanzi, Victor Shifrin, Michael Y. Sherman, Vladimir Gabai, Oleg Kisilev, Andrey Komissarov, Mikhail Grudinin, Maria Shartakova, Ekaterina Romanovskaya-Romanko, Yuri Kudryavets, Natalya Bezdenezhnykh, Oleksandra Lykhova, Nadiia Semesyuk, Antonio Concetti, Anatoly Tsyb, Marina Filimonova, Victoria Makarchuk, Raisa Yakubovsky, Andrey Chursov, Vita Shcherbinina, and Alexander Shneider
|
| 1829-1835 |
|
| The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer NSCLC recurrence and metastasis |
|
https://doi.org/10.18632/oncotarget.1282
Cheryl McFarlane, Suzanne McFarlane, Ian Paul, Kenneth Arthur, Michael Scheaff, Keith Kerr, Michael Stevenson, Dean A Fennell, and James A Johnston
|
| 1836-1843 |
|
| PTRF/Cavin1 decreases prostate cancer angiogenesis and lymphangiogenesis |
|
https://doi.org/10.18632/oncotarget.1300
Zeyad D Nassar, Hyeongsun Moon, Tam Duong, LiQi Neo, Michelle M Hill, Mathias Francois, Robert G Parton, and Marie-Odile Parat
|
| 1844-1855 |
|
| Insights into therapeutic resistance from wholegenome analyses of circulating tumor DNA |
|
https://doi.org/10.18632/oncotarget.1486
Luis A. Diaz, Jr, Mark Sausen, George A. Fisher, and Victor E. Velculescu
|
| 1856-1857 |
